Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials

• Autore: Kazmierski Wieslaw M
• Pubblicazione: Hoboken, : Wiley, 2011
• Descrizione fisica: 1 online resource (470 p.)
• Disciplina: 615/.7924
• Soggetto topico: Antiviral Agents -- therapeutic use; Antiviral agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation; Epidemiologic Studies; Chemistry, Pharmaceutical; Evaluation Studies as Topic; Investigative Techniques; Anti-Infective Agents; Epidemiologic Methods; Pharmacology; Therapeutic Uses; Health Care Evaluation Mechanisms; Chemistry; Biological Science Disciplines; Natural Science Disciplines; Quality of Health Care; Public Health; Pharmacologic Actions; Environment and Public Health; Health Care Quality, Access, and Evaluation; Chemical Actions and Uses; Health Care; Antiviral Agents; Health & Biological Sciences; Pharmacy, Therapeutics, & Pharmacology
• Persona (resp. second.): KazmierskiWieslaw M
• Note generali: Description based upon print version of record.
• Nota di contenuto: ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients ; 7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir ; 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection ; 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir ; 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate
• Sommario/riassunto: This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so
• Titolo autorizzato: Antiviral Drugs
• ISBN: 1-283-20363-4; 9786613203632; 0-470-92935-9; 0-470-92934-0
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910139613803321
• Lo trovi qui: Univ. Federico II